Want to see AU:RAC full AI Analyst Report?
RAC Stock Chart & Stats
AU$2.12
AU$0.02(0.98%)
At close: 4:00 PM EDT
AU$2.12
AU$0.02(0.98%)
Day’s Range― - ―
52-Week RangeAU$1.42 - AU$4.90
Previous CloseN/A
Volume42.13K
Average Volume (3M)80.06K
Market Cap
AU$419.59M
Enterprise ValueAU$367.74
Total Cash (Recent Filing)AU$34.29M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding196,068,940
10 Day Avg. Volume75,765
30 Day Avg. Volume80,056
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)10.91
Price to Sales (P/S)0.00
P/FCF Ratio-48.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetZero reported debt across each year lowers solvency risk and interest obligations. This gives the company more financial flexibility to fund oncology development and absorb setbacks than a similarly loss-making biotech carrying material leverage.
Prior Revenue ExpansionRevenue grew about 51% in FY2025 and 28% in FY2024, demonstrating prior expansion in reported activity. The FY2026 reversal is a major caveat, but this history provides evidence that revenue generation has been possible before.
Focused Oncology ProgramA focused program around bisantrene, or RC220, gives the company a defined oncology development thesis rather than a diffuse portfolio. If clinical work supports efficacy, this focus could concentrate capital and organizational effort.
Bears Say
Revenue CollapseFY2026 revenue fell 100% to zero after growth in prior years, removing current operating inflows and making the business dependent on financing or asset support. This weakens visibility into demand, commercialization progress, and internal funding capacity.
Persistent LossesPersistent operating and net losses, together with negative ROE of roughly -30% in FY2026, show that capital has not yet produced sustainable shareholder returns. Continued losses can constrain reinvestment and increase dilution risk as funding needs persist.
Ongoing Cash BurnOperating cash flow of approximately -8.2M in FY2026 and consistently negative free cash flow indicate that the business cannot currently fund itself. Unless revenue ramps materially, continued external funding may be required to sustain development.
Race Oncology Ltd. News
RAC FAQ
What was Race Oncology Ltd.’s price range in the past 12 months?
Race Oncology Ltd. lowest share price was AU$1.42 and its highest was AU$4.90 in the past 12 months.
What is Race Oncology Ltd.’s market cap?
Race Oncology Ltd.’s market cap is AU$419.59M.
When is Race Oncology Ltd.’s upcoming earnings report date?
Race Oncology Ltd.’s upcoming earnings report date is Mar 03, 2027 which is in 178 days.
How were Race Oncology Ltd.’s earnings last quarter?
Race Oncology Ltd. released its earnings results on Aug 25, 2026. The company reported -AU$0.039 earnings per share for the quarter.
Is Race Oncology Ltd. overvalued?
According to Wall Street analysts Race Oncology Ltd.’s price is currently Overvalued.
Does Race Oncology Ltd. pay dividends?
Race Oncology Ltd. does not currently pay dividends.
What is Race Oncology Ltd.’s EPS estimate?
Race Oncology Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Race Oncology Ltd. have?
Race Oncology Ltd. has 196,068,940 shares outstanding.
What happened to Race Oncology Ltd.’s price movement after its last earnings report?
Race Oncology Ltd. reported an EPS of -AU$0.039 in its last earnings report. Following the earnings report the stock price went up 0.952%.
Which hedge fund is a major shareholder of Race Oncology Ltd.?
Currently, no hedge funds are holding shares in AU:RAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Race Oncology Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:RAC Sentiment 96%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$30.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
50.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
117.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Race Oncology Ltd.
Headquartered in Sydney, Australia, Race Oncology Limited is a precision oncology company focused on advancing its lead therapeutic, Zantrene. This potent small molecule compound acts as an inhibitor of the fatso/fat mass and obesity associated protein (FTO) and is currently undergoing Phase II/III clinical trials. Zantrene is being investigated for its potential to treat a range of cancers, including melanoma, clear cell renal cell carcinoma, acute myeloid leukaemia, breast cancer, and ovarian cancer. The company maintains an active preclinical research program with the University of Newcastle, focusing on Zantrene, and has also forged a strategic alliance with the University of Wollongong to assess various formulations of the drug. Established in 2011, Race Oncology Limited adopted its current name in July 2016, having previously operated as Coronado Resources Limited.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―